Latest frontotemporal lobar degeneration Stories

Penn-designed non-invasive MRI screening method is cost-effective, statistically powerful When trying to determine the root cause of a person's dementia, using an MRI can effectively and non-invasively screen patients for Alzheimer's disease or Frontotemporal Lobar Degeneration (FTLD), according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania. Using an MRI-based algorithm effectively differentiated cases 75 percent of the time, according...

NEW YORK, March 7, 2012 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) announced today the recipients of their fifth annual research award, Frontotemporal Degeneration Drug Discovery Program. The goal of the program is to accelerate the development of novel therapies for frontotemporal degeneration (FTD). The ADDF/AFTD program awarded $300,000 to three academic scientists developing...

New research finds a marker used to detect plaque in the brain may help doctors make a more accurate diagnosis between two common types of dementia – Alzheimer's disease and frontotemporal lobar degeneration (FTLD). The study is published in the November 30, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology. "These two types of dementia share similar symptoms, so telling the two apart while a person is living is a real challenge, but important so...

(Ivanhoe Newswire) -- Alzheimer's disease and frontotemporal lobar degeneration (FTLD) are two of the most prevalent forms of neurodegenerative disorders. Researchers have analyzed changes in gene expression in the aging and diseased brain, finding new clues to the biology of normal aging and neurodegenerative diseases.In this report, an international team of researchers analyzed and compared changes in gene expression associated with aging and disease in a region of the brain known to be...

Alzheimer's disease and frontotemporal lobar degeneration (FTLD) are two of the most prevalent forms of neurodegenerative disorders. In a study published online today in Genome Research (www.genome.org), researchers have analyzed changes in gene expression in the aging and diseased brain, finding new clues to the biology of normal aging and neurodegenerative diseases.Recent studies have identified changes in how genes are read, or expressed, in the brain either during aging or with...

Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration (FTLD) are characterized by protein clumps in brain and spinal-cord cells that include an RNA-binding protein called TDP-43. This protein is the major building block of the lesions formed by these clumps. In a study published in the Journal of Clinical Investigation, a team led by Virginia M.-Y. Lee, PhD, director of Penn's Center for Neurodegenerative Disease Research, describes the first...

Researchers at the Mayo Clinic campus in Florida have found a clue as to how some people develop a form of dementia that affects the brain areas associated with personality, behavior, and language.In the Nov. 17 online issue of the American Journal of Human Genetics, the scientists write that they discovered a link between two proteins "” progranulin and sortilin "” they say might open new avenues for the treatment of frontotemporal lobar degeneration (FTLD), which occurs in the frontal...

Frontotemporal lobar degeneration (FTLD) refers to a group of disorders associated with degeneration of the frontal and temporal lobes of the brain. Symptoms include dementia, aphasia, and semantic disorders. Mutation of the gene for PGRN is associated with the most common form of FTLD, which is also characterized by inclusions of TDP-43 protein in the brain. Abnormal accumulation of TDP-43 has also been linked with amyotrophic lateral sclerosis (ALS).While it is clear that a reduction in...

In an international study of patients with a devastating type of dementia that often strikes in middle age, researchers have found intriguing evidence that career choice may influence where the disease takes root in the brain.The study was led by Baycrest's Rotman Research Institute in collaboration with the Memory and Aging Centre at the University of California, San Francisco and several U.S. and European clinical sites. It appears online today in the Article in Press section of the journal...

NEW YORK, April 7 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Dementias (AFTD) announced today the recipients of their third annual research award, Frontotemporal Dementia Drug Discovery Program. The goal of the program is to accelerate the development of novel therapies for frontotemporal dementia (FTD). The program will provide a total of $1,200,000 in research grants over four years. The ADDF/AFTD program awarded...